JPWO2020035554A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020035554A5
JPWO2020035554A5 JP2021506258A JP2021506258A JPWO2020035554A5 JP WO2020035554 A5 JPWO2020035554 A5 JP WO2020035554A5 JP 2021506258 A JP2021506258 A JP 2021506258A JP 2021506258 A JP2021506258 A JP 2021506258A JP WO2020035554 A5 JPWO2020035554 A5 JP WO2020035554A5
Authority
JP
Japan
Prior art keywords
alkyl
benzamide
diethylamino
ethyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501315A5 (https=
JP2022501315A (ja
JP7512251B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071903 external-priority patent/WO2020035554A1/en
Publication of JP2022501315A publication Critical patent/JP2022501315A/ja
Publication of JPWO2020035554A5 publication Critical patent/JPWO2020035554A5/ja
Publication of JP2022501315A5 publication Critical patent/JP2022501315A5/ja
Application granted granted Critical
Publication of JP7512251B2 publication Critical patent/JP7512251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506258A 2018-08-15 2019-08-15 病的炎症の新しい医療 Active JP7512251B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18189194 2018-08-15
EP18189194.6 2018-08-15
PCT/EP2019/071903 WO2020035554A1 (en) 2018-08-15 2019-08-15 A new medical treatment for pathologic inflammation

Publications (4)

Publication Number Publication Date
JP2022501315A JP2022501315A (ja) 2022-01-06
JPWO2020035554A5 true JPWO2020035554A5 (https=) 2022-08-17
JP2022501315A5 JP2022501315A5 (https=) 2022-08-17
JP7512251B2 JP7512251B2 (ja) 2024-07-08

Family

ID=63294023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506258A Active JP7512251B2 (ja) 2018-08-15 2019-08-15 病的炎症の新しい医療

Country Status (10)

Country Link
US (1) US11896564B2 (https=)
EP (1) EP3836912B1 (https=)
JP (1) JP7512251B2 (https=)
CN (1) CN112770736B (https=)
AU (1) AU2019322564A1 (https=)
BR (1) BR112021001984A2 (https=)
CA (1) CA3108361A1 (https=)
IL (1) IL280548A (https=)
MX (1) MX2021001349A (https=)
WO (1) WO2020035554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703036B (zh) * 2018-08-15 2025-05-27 法玛西尔有限公司 取代的苯甲酰胺及其在疗法中的用途
US11717500B2 (en) * 2020-02-03 2023-08-08 Pharmacyl Ab Treatment of spondyloarthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (https=) 1961-07-25
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6518312B2 (en) 2000-07-05 2003-02-11 Active Biotech Ab Immune enhancement
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
WO2005025498A2 (en) 2003-09-08 2005-03-24 Corus Pharma Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
DE102004011720B4 (de) 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
CA2649256C (en) * 2006-04-13 2013-09-10 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease
RU2469724C2 (ru) * 2007-12-18 2012-12-20 Мейдзи Сейка Фарма Ко., Лтд. Профилактическое или терапевтическое вещество при воспалительных болезнях кишечника
WO2018037103A1 (en) * 2016-08-26 2018-03-01 Idogen Ab Procainamide for treating immune disorders and for modulating ido expression

Similar Documents

Publication Publication Date Title
HRP20120505T1 (hr) Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe
JP2019034943A5 (https=)
HRP20090577T8 (en) Use of crth2 antagonist compounds in therapy
JP2010524947A5 (https=)
RU2009136445A (ru) Способ получения высокочистого празугрель гидрохлорида
JP2019532928A5 (https=)
JP2017504576A5 (https=)
JP2013518050A5 (https=)
JP2014502979A5 (https=)
JP2017523225A5 (https=)
JP2020502047A5 (https=)
RU2008102968A (ru) Производные изохинолина в качестве ингибиторов rho-киназы
JP2018533593A5 (https=)
JP2015535847A5 (https=)
JP2015508068A5 (https=)
JP2010522711A5 (https=)
JP2021522327A5 (https=)
RU2019128534A (ru) Химические соединения для лечения туберкулеза
JP2022501315A5 (https=)
JP2015504917A5 (https=)
JP2009040767A5 (https=)
JPWO2020035554A5 (https=)
JP2019529501A5 (https=)
JP2024508698A (ja) 再生器官修復のためのyap転写活性の小分子アクチベーター
JPWO2023072257A5 (https=)